GlassScriptPhysician profile
Anthony J Ng
NPI 1649202367
$17,898.85
in general payments reported to CMS, 2019-2025
30 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,343 · 2020: $3,514 · 2021: $2,610 · 2022: $2,013 · 2023: $2,287 · 2024: $2,158 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,418.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,002.58 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $3,863.68 | 2019-2025 | |
| Redhill Biopharma INC. | $2,553.09 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Abbvie INC. | $2,175.99 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $614.38 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $504.37 | 2019-2022 | |
| Vivus LLC | $473.28 | 2021-2025 | Pancreaze |
| Merck Sharp & Dohme LLC | $426.25 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Nestle Healthcare Nutrition INC. | $363.28 | 2021-2023 | |
| Ardelyx, INC. | $358.46 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $351.95 | 2019-2023 | Ocaliva |
| Pfizer INC. | $250.39 | 2019-2022 | |
| Allergan, INC. | $234.59 | 2019 | |
| Aimmune Therapeutics, INC. | $232.10 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $220.57 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $206.08 | 2019 | |
| Dova Pharmaceuticals | $142.85 | 2019 | |
| Celgene Corporation | $141.67 | 2022-2023 | Zeposia |
| Sirtex Medical INC | $134.48 | 2023 | Sir-Spheres Microspheres |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Currax Pharmaceuticals LLC | $92.71 | 2022-2024 | Contrave |
| Intra-Sana Laboratories | $85.24 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Olympus America INC. | $80.66 | 2023 | Evis Exera Lll Colonovideoscope |
| Novo Nordisk INC | $61.84 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $60.49 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $59.09 | 2023-2025 | Voquezna |
| Exact Sciences Corporation | $47.79 | 2023-2025 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $23.51 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $15.00 | 2019 | |
| Shionogi INC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.